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Relationship between initial PSA density with future PSA kinetics
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surveillance
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The objective of our study is to examine the correlation between PSA density (PSAd) at the time of
diagnosis with PSAvelocity (PSAV), PSA doubling time and tumour progression, on repeat biopsy,
in men with prostate cancer on active surveillance. Data from 102 patients with clinically localized
prostate cancer on active surveillance in the period between 1992 and 2007, who had the necessary
parameters available, were collected. PSAd was calculated and correlated with PSAV, PSA doubling
time (PSADT), Gleason score at diagnosis and local progression on repeated biopsies. PSAV was
0.64 and 1.31ngml
–1 per year (P¼0.02), PSADTof 192 and 113 months (P¼0.4) for PSAd below and
above 0.15, respectively. The rate of detecting high Gleason score (X7) at diagnosis was 6 and 23%
for PSAd below and above 0.15, respectively. A total of 101 patients underwent at least a second
biopsy and the incidence of upgrading was 10 and 31% for PSAd below and above 0.15, respectively
(P¼0.001). Although low PSAd is an accepted measure for suggesting insignificant prostate cancer,
our study expands its role to indicate that PSAd o0.15 may be an additional clinical parameter that
may suggest indolent disease, as measured by future PSAV and repeat biopsy over time.
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Introduction
There is great disparity between the incidence and
mortality of prostate cancer. There is an approximate
15% risk of men being diagnosed with prostate cancer
during their lifetime and only 3% lifetime risk of death
from the disease.
1 Furthermore, autopsy studies have
found that 60–70% of older men harbour prostate
cancer.
2 Moreover, results from prostate cancer preven-
tion studies
3 indicate that the rate of finding cancer
on biopsy approximates 25%. Finally, evidence from
recently conducted randomized screening trials
4 suggest
that screening for early prostate cancer and subsequent
treatment results in improvement in survival, but
approximately 48 men require treatment to save one life.
Thus, it is clear that more men are being diagnosed with
prostate cancer than need be and that active surveillance
for early prostate cancer is appealing. The largest
experience of active surveillance to date has reported
an approximate 30% progression rate with a median
follow-up of 6.8 years.
5 Several criteria exist in attempt-
ing to identify potentially insignificant prostate cancer,
including serum PSA level, PSA density (PSAd), Gleason
score and cancer volume on prostate biopsy. The use of
PSAd o0.15 as one measure of potentially insignificant
prostate cancer is well established. These studies have
been conducted on radical prostatectomy specimens where
true prostate cancer volume, Gleason score and histological
stage were correlated with PSAd at diagnosis.
PSA velocity (PSAV) is one of the important parameters
for predicting the behaviour and prognosis of prostate
cancer in men undergoing treatment. D’Amico et al.
6
reported that a greater pretreatment PSAV is associated
with a shorter time of disease-specific mortality.
Whether PSAd correlates with future cancer progres-
sion, as measured by PSA kinetics or cancer upgrading,
is unknown. The aim of our study is to examine the
correlation between diagnostic PSAd and subsequent
PSA kinetics, serum testosterone and tumour upgrading
on follow-up in men with prostate cancer on active
surveillance.
Materials and methods
The McGill University Health Center has been conduct-
ing an active surveillance protocol for men with prostate
cancer for several years.
7 Of these men, 102 cases were
enrolled in this study based on the availability of
complete data. Prostate volume was measured using
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www.nature.com/pcantransrectal ultrasound (TRUS) at the time of prostatic
biopsy. Prostate volume was measured as a prolate ellipse,
calculated as: height length width p/6. Width was
defined as the maximal transverse diameter at midgland
level, length was defined as the distance from the
proximal external sphincter to the urinary bladder and
height was measured as the midsagittal plane.
All biopsies were retrospectively reviewed by one of
two genitourinary pathologists. Considering the biopsy
template, we published before
7 that some of those patients
were initially diagnosed by sextant biopsy, whereas others
were diagnosed by the current standardized biopsy
template of X10 samples. Repeated biopsies for the
whole cohort were done using the current standardized
biopsy template for the whole cohort.
Serum PSA measurement used for PSAd was the value
observed at presentation before TRUS-guided biopsy.
PSAV was calculated using linear regression of all the
available PSA data. PSA doubling time was measured
using slope regression method of all available PSA
values. Gleason score was considered low if it was p6,
and was considered high when it was X7. Factors
correlating with tumour upgrading were studied. Statis-
tical analysis was done using Pearson w
2, Fisher’s exact
test and Student’s t-test. Multivariate analysis was done
using General Linear Model. A cutoff value for PSAd of
0.15 was used to correlate with PSA kinetics, Gleason
score and tumour upgrading. Tumour upgrading was
defined as progression from low grade (Gleason p6) to
high grade (Gleason X7) or a detection of any new
Gleason pattern X4 on repeat biopsies. Exclusion criteria
included patients receiving medications for BPH in the
form of 5a-reductase inhibitors, because of their possible
effect on serum PSA, prostate volume and serum
testosterone measurements.
Results
The characteristics of the patient cohort are described in
Table 1. The mean age of the patients was 66 years. The
mean serum PSA at diagnosis was 5.9ngml
–1 and the
mean PSAd was 0.14. Our patient cohort had a median
number of PSAvalues of 5 (range 3–13). The mean PSAV
was 0.88ngml
–1 per year and the mean PSA doubling
time (PSADT) was 172 months. The median number of
positive cores was 1, the median percentage of positive
cores was 16% and the median percentage of tumour
volume in the positive cores was 10%. The mean serum
testosterone was 12.7ngml
–1 and the mean level of
serum free testosterone was 23.4pgml
–1. A total of 101
patients included in the study had at least a second
biopsy during follow-up and 47, 18 and 7 patients had
third, fourth and fifth biopsies, respectively. Of the
patients in the study, 90 and 12 were diagnosed with low
and high Gleason score cancers, respectively.
The duration of follow-up ranged from 24 to 172
months, with a mean of 61 months. In relation to PSAd,
PSAV was 0.64 and 1.31ngml
–1 per year (P¼0.02),
PSADT of 192 and 113 months (P¼0.4), serum free
testosterone 34.2 and 19.5pgml
–1 (P¼0.0005) and serum
total testosterone 13.3 and 12.5ngml
–1 (P¼0.6) for PSAd
below and above 0.15, respectively. The rate of detecting
high Gleason score at diagnosis was 6 and 23% for PSAd
below and above 0.15, respectively (P¼0.01). Of the 101
patients who underwent at least a second biopsy, the rate
of upgrading was 10 and 31% for PSAd below and above
0.15, respectively (P¼0.001). In addition, there was a
tendency for cases with PSAd o0.15 to present with only
a single positive core, whereas cases with PSAd 40.15
tended to have more than one positive core of the
prostate (P¼0.08). Table 2 demonstrates the correlations
between PSAd and different variables.
On studying tumour upgrading, most of the cases that
showed upgrading had their Gleason score change from
p6t o46, except two cases with initial Gleason score 7
(4þ3) that developed new patterns 4 and 5, changing
their score to 8 and 9. Both PSAd and PSAV significantly
correlated with tumour upgrading on univariate analy-
sis, whereas only PSAd remained to be independent
significant factor predicting progression on multivariate
analysis. Table 3 demonstrates univariate analysis of
factors predicting tumour upgrading on repeated biopsy.
Multivariate analysis was performed (Table 4), where
PSAd represents PSAd with a cutoff value of 0.15 and
PSAV represents PSAV with a cutoff value of 0.75.
Multivariate analysis showed PSAd to be an indepen-
dent factor for predicting tumour upgrading on repeat
biopsy, whereas it showed a strong trend to predict PSAV
on follow-up. Twenty-five patients had PSAd ranging
Table 1 Patient characteristics




Mean serum PSA at diagnosis (ngml
–1) 5.9 (0.18–20.4)
Mean PSAd at diagnosis 0.14 (0.01–1.3)
Mean PSAV (ngml
–1 per year) 0.88 (0–9.6)
Mean PSADT (months) 172 (6–500)
Mean serum total testosterone (ngml
–1) 12.7 (0.4–19)
Mean serum free testosterone (pgml
–1) 23.4 (0.1–46.9)
Median number of positive cores 1 (1–6)




% of tumour volume in the positive cores
Median 10 (2–85)
Number of patients with o50% tumour 94
Number of patients with X50% tumour 8
Gleason score at diagnosis
Low (o7) 90
High 12









Abbreviations: PSAd, PSA density; PSADT, PSA doubling time; PSAV,
PSA velocity.
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on repeated biopsy. None of those five patients had
PSAd o0.15. One patient had PSAd of exactly 0.15, two
patients of 0.16 and two patients of 0.17.
Interestingly, serum PSA at diagnosis was not a
significant factor predicting PSAV, although it was of
significance predicting tumour upgrading. Studying the
changes of PSAd over time during repeated biopsy, it
was clear that there is a tendency for each group of
patients with PSAd p0.15 and 40.15 to remain in their
initial PSAd group. However, of patients with initial
PSAd 40.15 (35 patients), we had three patients (8.5%)
that showed a drop of PSAd to p0.15. Their drop in
PSAd can be explained perhaps by increased prostate
volume over time (follow-up of 24 months). Two patients
had initial Gleason score of 6 that inspite of a change in
PSAd into lower category due to increased prostate
volume they still showed upgrading into Gleason score
of 7. The third patient had initial Gleason score of 7
(3þ4) that did not change during follow-up. On the
other hand, of the patients with initial PSAd p0.15, we
had 10 patients (15%) that showed an increase in their
PSAd into 40.15 category during follow-up, which can
perhaps be attributed to the higher PSAV in that group
(median PSAV¼1). Tables 5 shows PSAd measurements
changes over time. A Supplementary Table is available
online showing the results of prostate volume measure-
ments for each patient during follow-up.
Discussion
Active surveillance is an established option for the
management of selected men with localized prostate
cancer.
5 Both the European
8 and the National Compre-
hensive Cancer Network
9 guidelines recommend the use
of PSAV in the follow-up of cases on active surveillance
and consider higher PSAV to be a sign of progression
that require treatment. The National Comprehensive
Cancer Network defined PSAV 40.75 to be a sign of
progression for prostate cancer for cases on active
surveillance, whereas the European guidelines did not
define a value of PSAV indicative of progression. Many
studies
8,10 have found a correlation between initial
serum PSA and future PSAV, in which high initial serum
PSA was found to be associated with high PSAV and





p10 77 17 0.8
410 6 1
p4 20 1 0.05
446 3 1 7
PSAd
p0.15 58 8 0.03
40.15 25 10
PSAV
p0.75 56 7 0.03
40.75 27 11
Positive cores
o3 74 16 0.9
X39 2
Abbreviation: PSAd, PSA density; PSAV, PSA velocity.
















Abbreviations: PSAd, PSA density; PSAV, PSA velocity.
Table 5 PSAd changes during follow-up
Initial PSAd Follow-up PSAd
o0.15 40.15
o0.15 (66 patients) 56 patients (85%) 10 patients (15%)
40.15 (35 patients) 3 patients (8.5%) 32 patients (91.5%)
Abbreviation: PSAd, PSA density.
Table 2 PSA density at diagnosis and PSA kinetics and repeat
biopsy over time
PSAd p0.15 40.15 P-value
PSAV 0.64 1.31 0.02
PSAV
p0.75 47 17 0.02
40.75 20 18
PSADT 192 113 0.4
Gleason
Low 63 27 0.01
High 4 8
Positive cores
1 core 47 19 0.08
412 0 1 6
Total testosterone 13.3 12.5 0.6
Free testosterone 34.2 19.5 0.0005
Repeat biopsy
Same grade 59 24 0.001
Upgrading 7 (10%) 11 (31%)
Abbreviations: PSAd, PSA density; PSADT, PSA doubling time; PSAV, PSA
velocity.
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not find a correlation between initial serum PSA and
PSAV on follow-up, although it was of significant value
in predicting tumour upgrading on repeat biopsy.
However, PSAd at the time of the diagnosis of prostate
cancer with subsequent PSAV showed a significant
correlation, as PSAd o0.15 was associated with a lower
PSAV (mean of 0.64), whereas PSAd 40.15 was
associated with a markedly higher PSAV (mean of
1.31). Furthermore, higher PSAd correlated indepen-
dently with greater rates of tumour upgrading on repeat
biopsy with 31% for cases with PSAd 40.15. Conti et al.
11
estimated an upgrading rate for cases suitable for active
surveillance of 28%. Smaldone et al.
12 demonstrated a
rate of upgrading reaching 27% for cases suitable for
active surveillance. In our cohort, we had a similar rate of
upgrading for cases with PSAd 40.15, whereas sig-
nificantly much lower rate of upgrading (10%) for cases
with PSAd p0.15. Of course PSAd requires prostate
volume measurement, which can be variable by TRUS.
Although the ellipsoid formula is not perfect, some
13,14
have confirmed its accuracy for estimating prostate
volume and its close correlation with pathological
prostatic volume. To date, the literature supports the
use of TRUS-based prostate volume measurements, and
as it is now used routinely to conduct prostate biopsy, we
feel that measuring prostate volume using TRUS to
determine PSAd remains a clinically relevant tool. Our
analysis showed that in our cohort there was a mean
increase in prostate volume of 10% over time, whether
this is variability of TRUS volume measurements or an
actual increase over time is unknown. The tendency to
keep within the same PSAd group during follow-up is
another factor confirming the accuracy of our prostate
volume measurements, where the majority of patients
within initial PSAd group tended to remain within the
same group during a mean follow-up of 5 years.
Although we observed a trend towards longer PSADT
in cases of low PSAd, this did not achieve statistical
significance. Some recent studies
15,16 investigated the use
of PSAV and PSADT on the same group of patients to
predict high-risk prostate cancer and concluded that
PSAV is a more useful parameter than PSADT to identify
men with life-threatening disease.
Out of our 18 patients that developed tumour upgrad-
ing, 10 patients were managed by radical prostatectomy,
4 patients by external beam radiation, 2 patients by
brachytherapy and 2 patients refused intervention and
kept on active surveillance. Gleason score following radical
prostatectomy was persistent with the biopsy findings.
There is accumulating literature suggesting an associa-
tion between low serum testosterone with prostate cancer.
Yamamoto et al.
17 detected an association between low
serum testosterone at presentation with positive surgical
margins following radical prostatectomy and worsening
overall survival. Morgentaler
18 demonstrated the associa-
tion between low serum testosterone with higher Gleason
grade cancer. In addition, Nishiyami et al.
19reported that
intraprostatic dihydrotestosterone levels were signifi-
cantly reduced in men with Gleason X7 cancer compared
with men with Gleason score p6. Based on these studies,
we decided to also examine the relationship of serum
testosterone with PSAd in our cohort of patients on active
surveillance. Interestingly, we observed a similar relation-
ship in that in cases with higher PSAd (40.15) there
was a significantly lower serum free testosterone and
vice versa.
Conclusion
PSAd appears to be a reliable clinical parameter to
predict the behaviour of clinically localized prostate
cancer on active surveillance. Our data suggests that
cases with PSAd o0.15 can be followed up safely on
active surveillance, whereas cases with PSAd 40.15 are
at a higher risk of tumour progression and may be better
managed by definitive therapy.
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